Actively Recruiting
A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2026-05-13
90
Participants Needed
1
Research Sites
135 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a single-arm, open-label, multicenter phase II clinical trial aimed at evaluating the efficacy, safety, and pharmacokinetics of SHR-1826 in treating locally advanced or metastatic non-small cell lung cancer . The recommended dose of SHR-1826 was administered via intravenous infusion once every 3 weeks (Q3W), with each treatment cycle lasting 21 days until meeting protocol-defined treatment discontinuation criteria.
CONDITIONS
Official Title
A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18-75 years
- ECOG performance status score of 0 or 1
- Histopathologically confirmed advanced or metastatic non-small cell lung cancer
- Provide archived or fresh tumor tissue
- Experienced disease progression or intolerance after systemic anti-tumor therapy for advanced or metastatic disease
- At least one measurable lesion according to RECIST v1.1 criteria
- Expected survival of 3 months or more
- Adequate organ function
You will not qualify if you...
- Central nervous system metastasis or meningeal metastasis with clinical symptoms
- History of or concurrent other malignancies
- Untreated spinal cord compression
- Uncontrolled tumor-related pain
- Adverse events from prior therapy not recovered to CTCAE Grade 1 or less
- History of interstitial lung disease
- Severe cardiovascular or cerebrovascular diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Affiliated Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China, 250117
Actively Recruiting
Research Team
Y
Yijun Jia
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here